HC Wainwright Reaffirms Buy Rating for IN8bio (NASDAQ:INAB)

IN8bio (NASDAQ:INAB)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. HC Wainwright also issued estimates for IN8bio’s FY2029 earnings at $0.15 EPS and FY2030 earnings at $0.59 EPS.

Other research analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a research report on Thursday, January 22nd. Zacks Research raised IN8bio to a “hold” rating in a report on Thursday, January 15th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $4.00.

IN8bio Price Performance

Shares of NASDAQ:INAB opened at $1.89 on Friday. The stock has a market capitalization of $18.47 million and a P/E ratio of -0.42. The business has a 50-day moving average of $2.00 and a two-hundred day moving average of $1.98. IN8bio has a fifty-two week low of $1.17 and a fifty-two week high of $7.50.

IN8bio (NASDAQ:INAB) last released its earnings results on Thursday, March 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.08). As a group, research analysts expect that IN8bio will post -0.56 EPS for the current fiscal year.

Hedge Funds Weigh In On IN8bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Alyeska Investment Group L.P. increased its position in IN8bio by 1,060.8% during the fourth quarter. Alyeska Investment Group L.P. now owns 957,484 shares of the company’s stock worth $2,231,000 after buying an additional 875,000 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of IN8bio by 381.6% in the fourth quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock valued at $2,048,000 after buying an additional 724,637 shares during the last quarter. 683 Capital Management LLC acquired a new stake in shares of IN8bio in the fourth quarter valued at approximately $1,696,000. Stonepine Capital Management LLC bought a new position in shares of IN8bio during the 2nd quarter worth approximately $172,000. Finally, Two Sigma Investments LP bought a new position in shares of IN8bio during the 3rd quarter worth approximately $107,000. Institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.